Działalność Naukowa

Analizy Ekonomiczne

Budget Impact Analysis of Naltrexone in the treatment of alcohol-dependent patients in Poland »
Cost Utility Analysis of Sertindole in the treatment of schizophrenia in Poland in the general population of schizophrenic patients and the population of patients intolerant to at least one other antipsychotic agent: a five year Markov Model »
The cost-effectiveness analysis of Vildagliptin in type 2 diabetes in Poland »
The Budget Impact Analysis of Vildagliptin in type 2 diabetes in Poland »
The cost-effectiveness analysis of Varenicline for smoking cessation in Poland »
Cost-effectiveness analysis of Imiquimod (Aldara) versus podophyllotoxin in treatment of genital/perianal warts in Poland »
Cost-effectiveness analysis of Imiquimod (Aldara) versus no treatment in acting keratosis »
Cost-effectiveness analysis of Imiquimod (Aldara) versus no treatment in patients with superficial basal cell carcinoma and contraindication to surgical intervention/cryotherapy »
Budget Impact Analysis of Docetaxel reimbursement in induction chemotherapy of locally advance head and neck squamous cell carcinoma in Poland »
Cost effectiveness analysis of Docetaxel versus standard regimen as the induction chemotherapy of locally advance head and neck squamous cell carcinoma in Poland »
Cost Utility and Budget Impact of Sertindole in the treatment of schizophrenia in Poland »
The Cost Utility and Budget Impact Analysis of Sitagliptin (Januvia) in type 2 diabetes in Poland »
Cost Utility Analysis of Decotaxel versus standard regimen in the neoadjuvant therapy of locally advanced breast cancer in Poland »
Budget Impact Analysis of the continuation of Docetaxel reimbursement in the neoadjuvant therapy of locally advanced breast cancer and palliative therapy of metastatic breast cancer in Poland »
Comparative Cost Utility Analysis of long-acting insulin analogue (insulin detemir) and NPH insulin for the treatment of type 1 and type 2 diabetes and a Budget Impact Analysis of insulin analogue reimbursement in Poland »
The cost-effectiveness of insulin glulisine in type 2 diabetes in Poland »
The Budget Impact of Apidra (insulin glulisine) reimbursement in Poland »
Cost effectiveness analysis of Docetaxel versus other regimens in the adjuvant therapy of early and locally advanced breast cancer in Poland »
Cost effectiveness analysis of Docetaxel versus other regimens in the adjuvant therapy of early and locally advanced breast cancer in Poland »
Cost effectiveness of Dutasteride in the treatment of Bening Prostatic Hyperplasia (BPH) »
Budget Impact Analysis of Avodart (Dutasteride) in the treatment of Bening Prostatic Hyperplasia (BPH) in Poland »

Kontakt